Molecular Factors and Mechanisms Driving Multidrug Resistance in Uropathogenic Escherichia coli-An Update

Genes (Basel). 2022 Aug 6;13(8):1397. doi: 10.3390/genes13081397.

Abstract

The rapid emergence of multidrug-resistant (MDR) bacteria indisputably constitutes a major global health problem. Pathogenic Escherichia coli are listed among the most critical group of bacteria that require fast development of new antibiotics and innovative treatment strategies. Among harmful extraintestinal Enterobacteriaceae strains, uropathogenic E. coli (UPEC) pose a significant health threat. UPEC are considered the major causative factor of urinary tract infection (UTI), the second-most commonly diagnosed infectious disease in humans worldwide. UTI treatment places a substantial financial burden on healthcare systems. Most importantly, the misuse of antibiotics during treatment has caused selection of strains with the ability to acquire MDR via miscellaneous mechanisms resulting in gaining resistance against many commonly prescribed antibiotics like ampicillin, gentamicin, cotrimoxazole and quinolones. Mobile genetic elements (MGEs) such as transposons, integrons and conjugative plasmids are the major drivers in spreading resistance genes in UPEC. The co-occurrence of various bacterial evasion strategies involving MGEs and the SOS stress response system requires further research and can potentially lead to the discovery of new, much-awaited therapeutic targets. Here, we analyzed and summarized recent discoveries regarding the role, mechanisms, and perspectives of MDR in the pathogenicity of UPEC.

Keywords: SOS stress response system; mobile genetic elements; multidrug-resistance; uroptahogenic E. coli.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Drug Resistance, Multiple, Bacterial / genetics
  • Escherichia coli Infections* / drug therapy
  • Escherichia coli Infections* / genetics
  • Escherichia coli Infections* / microbiology
  • Humans
  • Urinary Tract Infections* / drug therapy
  • Urinary Tract Infections* / genetics
  • Urinary Tract Infections* / microbiology
  • Uropathogenic Escherichia coli* / genetics

Substances

  • Anti-Bacterial Agents

Grants and funding

This study was funded by National Science Centre, grant number 2019/35/B/NZ6/03996.